drugset
drugset / Trial / NCT06053983

Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome

NCT06053983 ↗

Phase 4 Completed 126 enrolled Rawalpindi Medical College
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will help us to compare atorvastatin and rosuvastatin in terms of their ability to reduce biomarkers of inflammation in patients of acute coronary syndrome

Timeline

Start
2023-01-01
Primary completion
2023-08-01
Completion
2023-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg —
Subject Rosuvastatin Small molecule 20 mg —

Indications

No indication recorded.